natgillin/translations-raw huggingface dataset:
ANGIVELSE AF AKTIVE STOFFER OG ANDRE STOFFER
QUANTITY OF THE ACTIVE SUBSTANCE(S)
ANGIVELSE AF AKTIVE STOFFER OG ANDRE STOFFER
STATEMENT OF ACTIVE SUBSTANCE
ANGIVELSE AF AKTIVE STOFFER OG ANDRE STOFFER
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCE(S)
ANGIVELSE AF AKTIVE STOFFER OG ANDRE STOFFER
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCES
ANGIVELSE AF AKTIVE STOFFER/AKTIVE STOFFER
STATEMENT OF ACTIVE SUBSTANCE
ANGIVELSE AF AKTIVT STOF
LIST OF EXCIPIENTS
ANGIVELSE AF AKTIVT STOF
STATEMENT OF THE ACTIVE SUBSTANCE
ANGIVELSE AF AKTIVT STOF OG HJÆLPESTOFFER Aktivt indholdsstof :
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS Active substance :
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER
MARKETING AUTHORISATION NUMBER(S)
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER
METHOD AND ROUTE(S) OF ADMINISTRATION
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER
OTHER SPECIAL WARNING(S), IF NECESSARY
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER
SPECIAL STORAGE CONDITIONS
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER
STATEMEN T O FAC TIVE SUBSTANC E(S)
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER
STATEMENT OF ACTIVE SUB STANCE(S)
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER
STATEMENT OF ACTIVE SUBTANCE(S)
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER
Summary of the safety profile
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER OG HJÆLPESTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER)
STATEMENT OF ACTIVE SUBSTANCE(S)
ANGIVELSE AF DE AKTIVE STOF OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
ANGIVELSE AF DE AKTIVE STOF OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ANGIVELSE AF DE AKTIVE STOFFER OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
ANGIVELSE AF DE AKTIVE STOFFER OG ANDRE INDHOLDSSTOFFER Aktivt stof :
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS Active substance:
ANGIVELSE AF DE AKTIVE STOFFER OG ANDRE NDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ANGIVELSE AF DE AKTIVE STOFFER OG ANDRE NDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
ANGIVELSE AF DE MRL-VÆRDIER
STATEMENT OF THE MRLs
ANGIVELSE AF DE(T) AKTIVE STOF(FER() OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCES
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER Aktivstoffer
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS Active Substance
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER Aktivt stof
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS Active substance:
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER Aktivt stof:
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT Active substance:
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER Hætteglas der indeholder lyofilisat:
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Vial containing lyophilisate:
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER Pulver:
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER SUBSTANCE(S) Powder:
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE NDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ANGIVELSE AF DE(T) AKTIVE STOFFER OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
ANGIVELSE AF DE(T) AKTIVE STOFFER OG ANDRE INDHOLDSSTOFFER Aktivt stof :
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS Active substance:
ANGIVELSE AF DE(T) AKTIVE STOFFER(FER) OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ANGIVELSE AF DET AKTIVE STOF
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
ANGIVELSE AF DET AKTIVE STOF
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ANGIVELSE AF DET AKTIVE STOF OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE AND OTHER INGREDIENT (S) (S)
ANGIVELSE AF DET AKTIVE STOF OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCE(S)
ANGIVELSE AF DET AKTIVE STOF OG ANDRE INDHOLDSSTOFFER Aktivt stof:
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT(S) Active substance:
ANGIVELSE AF DET AKTIVE STOF OG ANDRE INDHOLDSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ANGIVELSE AF DET AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCES
ANGIVELSE AF DET AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ANGIVELSE AF DET AKTIVE STOFOG ANDRE INDHOLDSSTOFFER
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
ANGIVELSE AF MRL-VÆRDIER‌
STATEMENT OF THE MRLs
ANGIVELSE AF MRL-VÆRDIER‌
STATEMENT OF THE MRLs‌
ANGIVELSE AF MRL-værdier.
STATEMENT OF THE MRLs
Angivelse af, at Lojuxta var teratogent i ikke-kliniske undersøgelser, og at kvinder i den fødedygtige alder ikke må være gravide og skal anvende effektiv antikonception, før behandlingen initieres.
That Lojuxta was teratogenic in non-clinical studies and that women of child-bearing potential must be non-pregnant and using effective contraception prior to initiating treatment.
Angiødem
Angioedema
angiødem (med fatal udgang), lægemiddeludslæt, toksisk hududslæt, nældefeber
angioedema (with fatal outcome), drug eruption, toxic skin eruption, urticaria
Angiødem*
Angioedema
Angiødem, erythema multiforme, urticaria, exfoliativ dermatitis, Stevens-Johnson syndrom, Quincks ødem, lysfølsomhed
Angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity
angiødem, pruritus, urticaria
angioedema, pruritus, urticaria
Angotensin II-receptorantagonister, såsom telmisartan, mindsker diuretisk fremkaldt kaliumtab.
Angiotensin II receptor antagonists attenuate diuretic induced potassium loss.
Angst
anxiousness,
Angst
feeling anxious
angst (1,7 % over for 2,6 %), insomni (2,7 % over for 2,8 %)
anxiety (1.7% vs 2.6%), insomnia (2.7% vs 2.8%)
angst (kronisk fornemmelse af angst og nervøsitet) diabetiske neuropatiske smerter (beskrives ofte som brændende, stikkende, sviende, jagende, skærende eller som et elektrisk stød.
generalised anxiety disorder (chronic feeling of anxiety or nervousness) diabetic neuropathic pain (often described as burning, stabbing, stinging, shooting or aching or like an electric shock.
angst (kronisk fornemmelse af angst og nervøsitet) diabetiske neuropatiske smerter (beskrives ofte som brændende, stikkende, sviende, jagende, skærende eller som et elektrisk stød.
generalised anxiety disorder (chronic feeling of anxiety or nervousness); diabetic neuropathic pain (often described as burning, stabbing, stinging, shooting or aching or like an electric shock.
Angst (N), søvnløshed (N, B)
Anxiety (N), Insomnia (N,B)
Angst Depression Nedsat libido Nervøsitet Unormale tanker
Anxiety Depression Libido decreased Nervousness Thinking abnormal
angst eller depression
for anxiety or depression
angst eller irritation
feeling anxious or irritated
angst irritabilitet
anxiety irritability
angst og humørforstyrrelser såsom depression, appetitforstyrrelser, vægtændring
anxiety and mood disorders such as depression, appetite disorders, weight change
angst og humørsvingninger (inklusive associerede symptomer)
anxiety and mood disorders (including associated symptoms)
Angst og nervøsitet
Anxiety
Angst Søvnforstyrrelse
Anxiety Sleep disorder
angst søvnighed.
anxiety sleepiness
Angst*, Depression*
Anxiety*, Depression
Angst*, depression*, insomni, irritabilitet
Anxiety*, depression*, insomnia, irritability
angst,
anxiety,
angst,
Syndrome†,
angst, depress- sion, træthed
Anxiety, depression, tiredness
angst, depression
Anxiety, depression
Angst, depression, delirium, agitation
Anxiety, depression, delirium, agitation
Angst, depression, emotionel labilitet, søvnløshed
Vascular disorders
Angst, depression, forvirring, uro, søvnløshed, hallucinationer
Anxiety, depression, confusion, agitation, inability to sleep, hallucinations
angst, depression, konfus tilstand
anxiety, depression, confusional state
Angst, depression, konfusion
Anxiety, depression, confusion
angst, depression, træthed
Anxiety, depression, tiredness
angst, depression, træthed, døsighed, prikkende, snurrende fornemmelse eller følelsesløshed i huden
Anxiety, depression, tiredness, drowsiness, tingling sensations (pins and needles)
angst, depression, træthedsfornemmelse og søvnbesvær;
anxiety, depression, feeling sleepy and difficulty sleeping;
Angst, desorientering, søvnløshed
anxiety, disorientation, insomnia
angst, forvirring
anxiety, confusion
Angst, forvirring, nedtrykthed, humørsvingninger, panikanfald
feeling anxious; feeling of confusion; depressed mood; mood changes; panic attack
angst, hovedpine, feber, træthed;
anxiety, headache, fever, tiredness;
Angst, irritabilitet, rysten eller skælven
Anxiety, irritability, shaking or trembling
angst, koncentrationsbesvær og hukommelsessvækkelse at mærke, se eller høre ting, der ikke findes, eller tro på ting, der ikke er virkelige, dystre tanker, ændret handlemåde
feeling anxious, having difficulty in concentrating and memory loss, feeling, seeing or hearing things that do not exist or believing in things that are not real, having gloomy thoughts, changing how you act.
angst, konfusion
Anxiety Confusion
angst, konfusion, affektlabilitet, nedsat libido
anxiety, confusional state, affect lability, libido decreased
Angst, ophidselse
Anxiety, agitation
angst, søvnbesvær
anxiety, difficulty sleeping
Angst, søvnbesvær, forvirring, hallucinationer Uklart syn, synsforstyrrelser
Anxiety, difficulty sleeping, confusional state, hallucination Blurred vision, visual disturbance
Angst, søvnforstyrrelser Konfusion
Anxiety, sleep disturbance Confusion
Angst, søvnforstyrrelser, døsighed
Anxiety, sleep disorders, drowsiness
Angst, søvnløshed
Anxiety, insomnia
Angst, søvnløshed, søvnforstyrrelser
Anxiety, insomnia, sleep disorder
Angst.
anxiety
Angst.
Anxiety.
angst/depression
anxiety/depression
Angstc, insomnia
Anxietyc, insomnia
angstdæmpende medicin såsom alprazolam
medicines for anxiety such as alprazolam
angstfornemmelse
feeling anxious
Angstfølelse
Feeling anxious
angstfølelse
feelings of anxiety
Angstfølelse, søvnløshed (insomni)
feeling anxious, difficulty sleeping (insomnia)
Angstlidelser og -symptomer
Anxiety disorders and symptoms
Angstsymptomer, forvirring og desorientering, depression, humørsvingninger, mareridt, hallucinationer, forstyrret sindstilstand
anxiety symptoms, confusion and disorientation, depression, mood changes, nightmare, hallucination, mental disorders
Angående den fuldstændige indikation, incl. larvestadier, læs indlægssedlen.
For the complete indication, including the larval stages, read the package leaflet.
Anhidrose
Agranulocytosis
Anhidrose
Drug-induced
Anidulafungin bør derfor ikke anvendes under graviditet.
Therefore anidulafungin is not recommended in pregnancy.
Anidulafungin er ikke et klinisk betydende substrat, en induktor eller hæmmer af cytochrom P450- isoenzymerne (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A).
Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A).
Anidulafungin udviser lineær farmakokinetik over et bredt spektrum af doser givet 1 gang dagligt (15- 130 mg).
Anidulafungin displays linear pharmacokinetics across a wide range of once daily doses (15-130 mg).
Anidulafungin virker fungicidt over for Candida, mens det for Aspergillus’ vedkommende hæmmer væksten af hyphae.
Anidulafungin has shown fungicidal activity against Candida species and activity against regions of active cell growth of the hyphae of Aspergillus fumigatus.
Anidulafungins farmakokinetik var ens blandt personer af europæisk, sort, asiatisk og latinamerikansk afstamning.
Anidulafungin pharmacokinetics were similar among Caucasians, Blacks, Asians, and Hispanics.
Animal Health Drammensveien 288 NO-0283 Oslo
Drammensveien 288 NO-0283 Oslo
Animal Health Drammensveien 288NO-0283 Oslo
Drammensveien 288 NO-0283 Oslo
Animal Health Siemensova 2717/4 CZ-155 00 Praha 5
Bayer s.r.o., Animal Health Siemensova 2717/4 CZ-155 00 Praha 5
animalsk insulin (især bovint insulin) til human insulin,
an animal insulin (especially a bovine insulin) to human insulin,
Ankler, ben og fødder kan hæve (væskeansamling)
Ankles, legs and feet may swell (fluid retention)
Ankyloserend e spondylitis
Ankylosing spondylitis
Ankyloserende spondylit og non-radiografisk aksial spondylartrit
Ankylosing spondylitis and non-radiographic axial spondyloarthritis
Ankyloserende spondylit og non-radiografisk aksial spondylartrit er betændelsessygdomme i rygraden.
Ankylosing spondylitis and non-radiographic axial spondyloarthritis are inflammatory diseases of the spine.
Ankyloserende spondylitis (Bekhterevs sygdom)
Ankylosing spondylitis (Bechterew’s disease)
ankyloserende spondylitis (en sygdom, der medfører inflammation og smerter i leddene i rygsøjlen)
ankylosing spondylitis (a disease causing inflammation and pain in the joints of the spine);
ankyloserende spondylitis (en sygdom, der medfører ledbetændelse og ledsmerter i rygsøjlen),
ankylosing spondylitis (a disease causing inflammation and pain in the joints of the spine);
Ankyloserende spondylitis aksial spondyloartritis uden radiografiske tegn på ankyloserende spondylitis er en inflammatorisk (betændelseslignende) sygdom i rygsøjlen.
Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, are inflammatory diseases of the spine.
Ankyloserende spondylitis er en betæ ndelsessygdom i rygraden.
Ankylosing spondylitis is an inflammatory disease of the spine.
Ankyloserende spondylitis hos voksne
Adult psoriasis
Ankyloserende spondylitis og aksial spondyloartritis uden radiografiske tegn på ankyloserende spondylitis er en inflammatorisk (betændelseslignende) sygdom i rygsøjlen.
Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis are inflammatory diseases of the spine.
Ankyloserende spondylitis(AS)
Ankylosing spondylitis (AS)
Ankyloserende spondylitis-respons
Ankylosing Spondylitis Response
Ankylosing Spondylitis Disease Activity Score C-Reactive Protein (AT-Placebo, N = 90; AT-Simponi 50 mg, N = 88; OSI-Placebo, N = 71; OSI-Simponi 50 mg, N = 71) n afspejler antal patienter med MRI-data ved baseline og uge 16
Ankylosing Spondylitis Disease Activity Score C-Reactive Protein (AT-Placebo, N = 90; AT-Simponi 50 mg, N = 88; OSI-Placebo, N = 71; OSI-Simponi 50 mg, N = 71) n reflects number of patients with baseline and week 16 MRI data
Anlæg lokalanæstesi af implantationsområdet, hvis det skønnes nødvendigt i samråd med patienten.
Anaesthetise the insertion area if deemed necessary and in consultation with the patient.
Anlæg lokalanæstesi af implantationsområdet, hvis det skønnes nødvendigt i samråd med patienten.
Anaesthetize the insertion area if deemed necessary and in consultation with the patient.
Anlæg stase (årepresse) om din arm.
Apply a tourniquet to your arm.
Anlæg stase.
Apply a tourniquet.
Anlæg staseslange om armen.
Apply a tourniquet to your arm
Anlæggelse eller fjernelse af katetre skal udføres mindst 12 timer efter administration af lave doser enoxaparinnatrium (20 mg en gang dagligt, 30 mg en eller to gange dagligt og 40 mg en gang dagligt) og mindst 24 timer efter administration af høje doser enoxaparinnatrium (0,75 mg/kg legemsvægt to gange dagligt, 1 mg/kg legemsvægt to gange dagligt eller 1,5 mg/kg legemsvægt en gang dagligt).
Placement or removal of a catheter should be performed at least 12 hours after the administration of low doses of enoxaparin sodium (20 mg once daily, 30 mg once or twice daily or 40 mg once daily) and at least 24 hours after administration of high doses of enoxaparin sodium (0.75 mg/kg bw twice daily, 1 mg/kg bw twice daily or 1.5 mg/kg bw once daily).
Anlæggelse eller udtagning af katetre skal udføres mindst 12 timer efter administration af lave doser enoxaparinnatrium (20 mg en gang dagligt, 30 mg en eller to gange dagligt og 40 mg en gang dagligt) og mindst 24 timer efter administration af høje doser enoxaparinnatrium (0,75 mg/kg legemsvægt to gange dagligt, 1 mg/kg legemsvægt to gange dagligt eller 1,5 mg/kg legemsvægt en gang dagligt).
Placement or removal of a catheter should be performed at least 12 hours after the administration of low doses of enoxaparin sodium (20 mg once daily, 30 mg once or twice daily or 40 mg once daily) and at least 24 hours after administration of high doses of enoxaparin sodium (0.75 mg/kg bw twice daily, 1 mg/kg bw twice daily or 1.5 mg/kg bw once daily).
Anmodning om at fortælle lægen om alle patientens sygdomme før behandlingen.
Request to inform the physician of all medical conditions before treatment.
Annopol 6B
Annopol 6B Poland
Annopol 6B - 03-236 Warszawa, Polen Laboratorios Servier, S.L, Avda. de los Madroños, 33 -28043 Madrid, Spanien
Annopol 6B - 03-236 Warszawa, Poland Laboratorios Servier, S.L, Avda. de los Madroños, 33 -28043 Madrid, Spain
Annopol 6B Polen
Annopol 6B Poland
Annopol 6B – 03-236 Warszawa, Polen
Annopol 6B – 03-236 Warszawa, Poland
Annopol 6B – PL-03-236 Warszawa, Polen Laboratorios Servier, S.L, Avda. de los Madroños, 33 -28043 Madrid, Spanien
Annopol 6B – 03-236 Warszawa, Poland Laboratorios Servier, S.L, Avda. de los Madroños, 33 -28043 Madrid, Spain
anode-elektrode: lag af sølvfolie og elektrisk ledende selvklæbende tape
anode electrode: layers of silver foil and electrically conductive adhesive tape
Anomal hjerterytme eller mangel på blodtilførsel til hjertet
abnormal heart rate or lack of blood flow to the heart
Anomale blodprøver, herunder øget antal hvide blodlegemer, lave kaliumniveauer.
abnormal blood test results, including increase in white blood cells, low potassium levels
Anonymiserede patientoplysninger – alder, køn og ætiologi for PAH
Anonymised patient details – age, sex and aetiology of PAH
Anordningen påvirker ikke injektionssprøjtens normale funktion, og sprøjten kan roteres i anordningen.
This does not affect normal operation of the syringe and the syringe can be rotated in the device..
Anoreksi
anorexia,
Anoreksi
Decreased appetite
Anoreksi
Leukocytes decreased
Anoreksi
Not known
Anoreksi
Uncommon: anorexia
Anoreksi (21 %) blev meget ofte indberettet i fase I og II studier med mifamurtid..
Anorexia (21%) was very commonly reported in phase I and II studies of mifamurtide
anoreksi (appetitløshed)
anorexia (lack of appetite)
anoreksi (appetitløshed), angst, følelsesmæssig ustabillitet
anorexia (loss of appetite), anxiety, emotional lability
anoreksi (appetitløshed);
anorexia (loss of appetite);
Anoreksi (G3/4: 0,6
Anorexia (G3/4: 0.6%)
Anoreksi (G3/4: 0,6 %)
Anorexia (G3/4: 1%); Decreased appetite
Anoreksi (G3/4: 0,6 %)
Anorexia (G3/4: 12.0%)
Anoreksi (G3/4: 0,6 %)
Anorexia (G3/4:0.6%)
Anoreksi (G3/4: 0,6%)
Anorexia (G3/4: 0.6%)
Anoreksi (G3/4: 0.6 %)
Anorexia (G3/4: 1.5%)
Anoreksi (G3/4: 1 %);
Anorexia
Anoreksi (G3/4: 1 %); Nedsat appetit
Anorexia (G3/4: 0.6%)
Anoreksi (G3/4: 1 %); Nedsat appetit
Anorexia (G3/4: 1%);
Anoreksi (G3/4: 1%); Nedsat appetit
Anorexia (G3/4: 1%); Decreased appetite
Anoreksi (G3/4: 1,5 %)
Anorexia (G3/4: 0.6%)
Anoreksi (G3/4: 1,5%)
Anorexia (G3/4: 1.5%)
Anoreksi (G3/4: 11,7 %)
Anorexia (G3/4:0.6%)
Anoreksi (G3/4: 11,7%)
Anorexia (G3/4: 11.7%)
Anoreksi (G3/4: 12,0 %)
Anorexia (G3/4: 12.0%)
Anoreksi (G3/4: 12,0%)
Anorexia (G3/4: 12.0%)
anoreksi (som kan være alvorlig)
anorexia (which may be severe)
anoreksi / nedsat appetit
anorexia / decreased appetite
Anoreksi Hyperglykæmi Hypokalcæmi Hypokaliæmi Hypomagnesiæmi Hypofosfatæmi
Anorexia Hyperglycaemia Hypocalcaemia Hypokalaemia Hypomagnesaemia Hypophosphatemia
Anoreksi Hyperkolesterolæmi Hypertriglyceridæmi
Anorexia Hypercholesterolemia Hypertriglyceridaemia
Anoreksi Hypoglykæmi
Anorexia Hyperglycaemia
Anoreksi Nedsat appetit Dehydrering
Anorexia Decreased appetite Dehydration
Anoreksi Nedsat appetit Hyperglykæmi
Anorexia Decreased appetite Hyperglycaemia
Anoreksi*
Anorexia
anoreksi, appetitløshed, hypokaliæmi
anorexia, decreased appetite, hypokalemia
Anoreksi, appetitløshed, vægttab (især ved kombination med natriumvalproat
Anorexia, loss of appetite, weight loss (especially when combined with sodium valproate)
anoreksi, diabetes mellitus, hyperkolesterolæmi, hypertriglyceridæmi, hyperlipidæmi
anorexia, diabetes mellitus, hypercholesterolaemia, hypertriglyceridaemia, hyperlipidaemia
Anoreksi, flatulens, mundsår, gastrointestinal blødning, gastroøsofageal reflukssygdom, pankreatit
Anorexia, , flatulence, mouth ulcer, gastrointestinal haemorrhage, gastroesophageal reflux disease, pancreatitis
Anoreksi, hypertriglyceridæmi, hypoalbuminæmi, hypofosfatæmi, nedsat appetit, tetani, type 2 diabetes mellitus, øget appetit
Anorexia, decreased appetite, hypertriglyceridaemia, hypoalbuminaemia, hypophosphataemia, increased appetite, tetany, type 2 diabetes mellitus
Anoreksi, hypofosfatæmi
Anorexia, hypophosphataemia
Anoreksi, let eller moderat (CTC-grad 1 eller 2)
Anorexia mild or moderate (CTC grade 1 or 2).
anoreksi, nedsat appetit, vægttab, hyperamylasæmi, hyperkolesterolæmi, diabetes mellitus, hyperglykæmi
anorexia, decreased appetite, weight decreased, hyperamylasaemia, hypercholesterolaemia, diabetes mellitus, hyperglycaemia
anoreksika eller amfetaminlignende psykostimulanter
anorexogenics or amphetamine-type psychostimulants
Anorektalt ubehag, oral paræstesi
Anorectal discomfort, oral parasthesia
Anorexi (nedsat appetit)
Anorexia (decreased appetite)
anorgasme,
blunted affectc
Anormal gråd
Abnormal crying
Anormal regulering af IL 12 og IL 23 er imidlertid blevet associeret med immunmedierede sygdomme såsom psoriasis, psoriasisartrit og Crohns sygdom.
However, abnormal regulation of IL 12 and IL 23 has been associated with immune mediated diseases, such as psoriasis, psoriatic arthritis and Crohn’s disease.
Anormale
Abnormal breath
Anormale kliniske tegn efter dag 16, udover de kliniske tegn anført ovenfor, og som forekom hos flere end 1% af de hunde, der fik oclacitinib, omfattede pyoderma, ikke-specificerede dermale knuder, otitis, histiocytom, cystitis, hudinfektioner med gærsvamp, pododermatitis, lipom, forstørrede lymfeknuder (lymfadenopati), kvalme, øget appetit og aggression.
After day 16, abnormal clinical signs in addition to those clinical signs listed above and occurring in greater than 1% of the dogs receiving oclacitinib included pyoderma, non-specified dermal lumps, otitis, histiocytoma, cystitis, yeast skin infections, pododermatitis, lipoma, enlarged lymph nodes (lymphadenopathy), nausea, increased appetite and aggression.
Anormale kliniske tegn efter dag 16, udover de kliniske tegn anført ovenfor, og som forekom hos flere end 1% af de hunde, der fik oclacitinib, omfattede pyoderma, ikke-specificerede dermale knuder, otitis, histiocytom, cystitis, hudinfektioner med gærsvamp, pododermatitis, lipom, lymfadenopati, kvalme, øget appetit og aggression.
After day 16, abnormal clinical signs, in addition to those clinical signs listed above and occurring in greater than 1% of the dogs receiving oclacitinib included pyoderma, non-specified dermal lumps, otitis, histiocytoma, cystitis, yeast skin infections, pododermatitis, lipoma, lymphadenopathy, nausea, increased appetite and aggression.
Anormale leverfunktionsprøver
Liver function test abnormal
Anormale nyrefunktionstests og/eller blod i urinen
Abnormal kidney function tests and/or blood in the urine
Anormaliteter i spiserøret, som forsinker tømning af spiserøret, såsom forsnævring eller akalasi
Abnormalities of the oesophagus which delay oesophageal emptying such as stricture or achalasia
Anoro (N=413) versus umeclidinium
ANORO (N = 413) versus
Anoro 55 mikrogram/22 mikrogram inhalationspulver, afdelt
ANORO 55 micrograms/22 micrograms inhalation powder, pre-dispensed
Anoro 55 mikrogram/22 mikrogram inhalationspulver, afdelt umeclidinium/vilanterol
ANORO 55 micrograms/22 micrograms inhalation powder, pre-dispensed umeclidinium/vilanterol
Anoro 55/22 mikrog inhalationspulver umeclidinium/vilanterol
ANORO 55/22 mcg inhalation powder umeclidinium/vilanterol